Good Health is Your Greatest Wealth……Virgil
Sarah Buckley's poem “Denied” skillfully highlights the intersecting roles of healthcare, politics, and socioeconomic iniquities in the context of medical practice. A personal and informative look at the causal roles of poverty and prostitution to …
See all stories on this topic »
The global outlook series on the Alternative Medicine Industry provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers a rudimentary …
See all stories on this topic »
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.
www.sys-con.com/node/2201006
LONDON (Reuters) – AstraZeneca said on Tuesday it was suing the Food and Administration after the U.S. regulator refused to delay the market entry later this month of generic versions of top-selling antipsychotic Seroquel. The drugmaker is seeking an injunction barring the FDA from granting final marketing approval of generic forms of the drug, whose chemical name is quetiapine, until December 2, 2012, or at least until a federal court has a chance to review the agency’s action. …
MUMBAI (Reuters) – Deutsche Bank cut its target price for Biocon Ltd shares by 9 percent to 215 rupees after Pfizer Inc ended a deal to sell insulin products made by the Indian drugmaker. “This issue raises its risk profile in this high-risk, capital-intensive business,” Deutsche Bank wrote in a research note. Biocon shares were trading at 253.75 rupees at 1.30 p.m. (0800 GMT), down 5.16 percent. The separation leaves India’s biggest biotech company without a partner to sell the insulin drugs in key global markets such as the United States. (Reporting by Abhishek Vishnoi; Editing by Ted Kerr)
MUMBAI (Reuters) – Pfizer Inc, the world’s largest drugmaker, has scrapped a deal to sell insulin products made by Biocon Ltd, leaving India’s biggest biotech company without a partner to sell the drugs in key global markets such as the United States. The two companies cited “individual priorities” as the reason for the split in a joint statement released on Tuesday, which immediately ends a relationship that stood to earn Biocon hundreds of millions of dollars in royalties. …
MUMBAI (Reuters) – India’s Biocon Ltd will retain milestone payments it received from Pfizer Inc as part of a deal that allowed the U.S. drugmaker to sell Biocon’s insulin products globally, Biocon’s chairman said, without providing details. Certain additional payments would also come from Pfizer, Kiran Mazumdar Shaw told CNBC-TV18 on Tuesday. “This (additional) income will get reflected in our quarterly numbers,” she said, declining to give details. …
You will be able to hear audio notifications for time, distance, and pace during your runs. Android lovers, be warned: your stint at exercise is coming to meet you: Zombies, Run! is coming to Android, as well.
See all stories on this topic »
Brain and eye problems have surfaced in astronauts who spent more than a month in space, marking a potential setback to plans for longer deep space missions, according to a US study.
By Denise Foley, Good Housekeeping You've seen the promise before — "Eat all your favorite foods and lose weight." The skeptic in you thinks, Are you kidding me? Eating all my favorite foods is how I gained weight in the first place.
See all stories on this topic »
LONDON (Reuters) – New research confirmed that all-metal artificial hips fail more often than other types, fuelling concerns about the devices and prompting a call from researchers on Tuesday for a ban. The analysis in The Lancet medical journal came two weeks after Britain’s medical regulator said nearly 50,000 Britons with metal-on-metal hips needed annual check-ups to monitor for problems, including exposure to toxic metals. …